Pacira BioSciences, Inc. - Q1 2026 Financial Results
Pacira BioSciences reported its first quarter 2026 financial results, with total revenues reaching $177.4 million, a 5% increase compared to the first quarter of 2025. This growth was driven by a 5% increase in EXPAREL net product sales to $143.3 million and a 15% increase in ZILRETTA net product sales to $26.8 million. The company also saw a 21% increase in ioveraΒ° net product sales, reaching $6.2 million. GAAP net income was $2.9 million, or $0.07 per share, a decrease from the previous year. Adjusted EBITDA was $40.2 million, down from $44.1 million in Q1 2025. The company completed enrollment in its Phase 3 registrational study for ZILRETTA in shoulder osteoarthritis and expects topline results by year-end. Pacira BioSciences reiterated its full-year 2026 guidance, projecting total revenues between $745 million and $770 million.